Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222833 · ClinicalTrials.gov registry record · Phase 4
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00222833 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 30 participants.
The verdict
NCT00222833, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure. This study also examines the safety of switching to aripiprazole with respect to changes in the clinical state, preexisting or emergent side-effects, how the brain processes information and changes in social functioning and quality of life.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222833
The ClinicalTrials.gov registry entry for NCT00222833 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00222833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222833 about?
NCT00222833 is a clinical study titled "The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia". This is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure. This study also examines the safety of switching to aripiprazole with respect to changes in the clinical state, pre...
What is the current status of trial NCT00222833?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2004-10. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00222833?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00222833?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.